Compare Johnson & Johnson (JNJ) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs PubMatic Inc — how do they compare? Johnson & Johnson trades at $260.87 (market cap $626.09B), while PubMatic Inc trades at $17.16 (market cap $804.41M). The key difference: Johnson & Johnson is far larger — about 778.3× PubMatic Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| JNJ | PUBM | |
|---|---|---|
Market Cap | $626.09B | $804.41M |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $17.78 |
52-Week Low | $172.78 | $6.28 |
Enterprise Value | $654.37B | $707.54M |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
PubMatic (PUBM) trades at $17.76, down slightly by 0.11% today. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Recent Q2 2026 earnings beat expectations with 10.5% revenue growth and a significant EPS surprise. The company is focusing on high-margin segments like mobile app and CTV advertising, supported by new AI product launches and executive appointments.
The outlook is cautiously optimistic with a consensus price target of $20.83, implying 17% upside. However, risks include persistent net losses, a high P/E ratio of 132, and competitive pressures in digital advertising. Analyst sentiment is split evenly between Buy and Hold ratings, reflecting uncertainty around near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
